Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

about

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

Item

http://www.wikidata.org/entity/Q46600089

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

@en

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

@nl

type

Item

label

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

@en

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

@nl

prefLabel

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

@en

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

@nl

P1476

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

@en

P2093

Ann C Collier

http://www.w3.org/2001/XMLSchema#string

Camlin Tierney

http://www.w3.org/2001/XMLSchema#string

Charles S Venuto

http://www.w3.org/2001/XMLSchema#string

Cindy J Bednasz

http://www.w3.org/2001/XMLSchema#string

Eric S Daar

http://www.w3.org/2001/XMLSchema#string

Gene D Morse

http://www.w3.org/2001/XMLSchema#string

Gregory E Wilding

http://www.w3.org/2001/XMLSchema#string

Kimberly Y Smith

http://www.w3.org/2001/XMLSchema#string

Margaret A Fischl

http://www.w3.org/2001/XMLSchema#string

Paul E Sax

http://www.w3.org/2001/XMLSchema#string

P2860

Q27009249

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.

P304

596-603

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FTD.0000000000000443

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29135907

http://www.w3.org/2001/XMLSchema#string

P932

5718358

http://www.w3.org/2001/XMLSchema#string